epithelial ovarian carcinoma . Am J Obstet Gynecol 1994 ; 170 : 974 – 979 ; discussion 979–980 . 5. Bristow RE Tomacruz RS Armstrong DK . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era
Search Results
Intraperitoneal Chemotherapy for Ovarian Cancer: Where Are We Now?
Pankaj Singhal and Shashikant Lele
CLO20-068: Incidence and Potential Predictors of Thromboembolic Events in Epithelial Ovarian Carcinoma Patients During Perioperative Period
Qingqing Zhou, Chenchen Zhu, Zhen Shen, Jing Zhu, Tianjiao Zhang, Min Li, Jiwei Qin, Lili Qian, Chuan Chen, Hanyuan Liu, Zhihao Xu, Dabao Wu, Björn Nashan, and Ying Zhou
Objective: To assess the incidence and the risk factors of venous thromboembolism (VTE) in patients with epithelial ovarian carcinoma (EOC) during perioperative period. Methods: A retrospective analysis was conducted on the patients with
Novel Non-Cytotoxic Therapy in Ovarian Cancer: Current Status and Future Prospects
Lainie Martin and Russell J. Schilder
. 20. Nishida N Yano H Komai K . Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma . Cancer 2004 ; 101 : 1364 – 1374 . 21
Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer
Kari E. Hacker, Shitanshu Uppal, and Carolyn Johnston
borderline ovarian tumors (BOTs) and low-grade epithelial ovarian carcinomas (LG-EOCs) Assess the role of surgery, chemotherapy and fertility/hormonal preservation in the management of BOTs and LG-EOCs The International Federation of Gynecology and
Germline PALB2 Variants and PARP Inhibitors in Endometrial Cancer
Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse
Research; AO, anaplastic oligodendroglioma; CUP, cancer of unknown primary; ESC, endometrial serious adenocarcinoma; HGSOC, high-grade serous ovarian carcinoma; IBC, invasive breast carcinoma; ICC, intrahepatic cholangiocarcinoma; IDC, invasive ductal
Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course
Jocelyn S. Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles J. Zaloudek, Stefanie Ueda, Eric A. Collisson, and Barry S. Taylor
to a previously identified BRCA2 germline mutation in a patient diagnosed with an MYC -amplified, TP53 -mutant ovarian carcinoma, who experienced a 32-month complete response to platinum therapy. 10 Moreover, this is a low-incidence variant; only
Surgery for Ovarian Cancer: Rationale and Guidelines
Benjamin E. Greer, Ron E. Swensen, and Heidi J. Gray
clinically unilateral stage I invasive epithelial ovarian carcinomas . Gynecol Oncol 2001 ; 80 : 56 – 61 . 5 Munoz KA Harlan LC Trimble EL . Patterns of care for women with ovarian cancer in the United States . J Clin Oncol 1997 ; 15 : 3408
Counterpoint: Intraperitoneal Chemotherapy: An Investigational Treatment in Ovarian Cancer
Robert F. Ozols
-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group. Southwestern Oncology Group, and Eastern Cooperative Oncology Group . J Clin Oncol
Point: Intraperitoneal Chemotherapy in the Management of Ovarian Cancer
Maurie Markman
mitoxantrone in the management of refractory ovarian carcinoma . J Clin Oncol 1990 ; 8 : 146 – 150 . 25 Berek JS Markman M Stonebraker B . Intraperitoneal interferon-α in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study
Ovarian Cancer Biomarkers: Current Options and Future Promise
Christine M. Coticchia, Jiang Yang, and Marsha A. Moses
of survival, but no improvement in the cure rate . Eur J Cancer 2002 ; 38 : 2435 – 2445 . 5. Omura GA Brady MF Homesley HD . Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology
